The FDA's Authority on Trial: How the Supreme Court's Shadow Docket Preserved Mifepristone Access

In a significant intervention on its emergency docket, the U.S. Supreme Court has temporarily blocked a lower court ruling that would have severely restricted nationwide access to the abortion medication mifepristone. The 7-2 decision, issued in mid-May 2026, ensures that the drug can continue to be prescribed via telehealth and dispensed through the mail while a high-stakes lawsuit brought by the state of Louisiana proceeds through the federal court system.[1][2]

The Supreme Court's order halts a mandate from the 5th U.S. Circuit Court of Appeals, which had effectively reinstated an in-person dispensing requirement for the medication across all 50 states. By granting the emergency stay, the justices preserved the regulatory status quo established by the Food and Drug Administration (FDA) in 2023, avoiding immediate disruptions to a healthcare network where medication now accounts for nearly two-thirds of all abortions in the United States.[6]

The legal battle, Louisiana v. FDA, represents the latest chapter in a sustained effort to challenge the federal government's authority over reproductive healthcare following the 2022 reversal of Roe v. Wade. In October 2025, Louisiana Attorney General Liz Murrill filed suit against the FDA, arguing that the agency's decision to allow remote prescribing of mifepristone actively undermined the state's near-total ban on abortion.

The core of Louisiana's argument centers on the concept of sovereign and financial injury. The state contends that by permitting out-of-state providers to mail mifepristone to Louisiana residents, the FDA is facilitating the circumvention of state law. Furthermore, Louisiana claims it suffers direct financial harm because its Medicaid program must absorb the costs of emergency room care for women who experience complications after taking the mailed medication.[5][6]

This approach to establishing legal standing is a direct response to the Supreme Court's unanimous 2024 decision in FDA v. Alliance for Hippocratic Medicine. In that case, the Court dismissed a similar challenge brought by a coalition of anti-abortion doctors, ruling that the physicians lacked Article III standing because they could not demonstrate a concrete, personal injury caused by the FDA's regulations. Louisiana's strategy attempts to clear that procedural hurdle by asserting injuries specific to the state itself.[1][3]

The regulatory framework at the center of the dispute is the FDA's Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. First approved in 2000, the drug was initially subject to strict rules requiring patients to obtain it in person from a certified healthcare provider. During the COVID-19 pandemic in 2021, the FDA temporarily suspended the in-person requirement to reduce viral transmission, allowing the medication to be mailed.[4]

In 2023, after reviewing extensive safety data and real-world evidence gathered during the pandemic, the FDA formally updated the REMS to permanently allow telehealth prescribing and mail-order dispensing. The agency concluded that the drug, which is typically used in combination with misoprostol, could be safely administered without a physical clinic visit.[4][6]

The current litigation began in a federal district court in Louisiana, where Judge David Joseph, a Trump appointee, initially declined to immediately block the FDA's rules. Instead, in April 2026, he paused the case for six months to allow the FDA to complete an ongoing internal review of the drug's safety protocols. Dissatisfied with the delay, Louisiana quickly appealed to the 5th Circuit Court of Appeals.[4][6]

On May 1, 2026, a unanimous three-judge panel of the 5th Circuit sided with Louisiana. The appellate court concluded that the state was highly likely to succeed on the merits of its claim that the FDA's 2023 rule change was "arbitrary and capricious" under the Administrative Procedure Act. The panel's order immediately reinstated the in-person dispensing requirement nationwide, prompting swift emergency appeals to the Supreme Court by the drug's manufacturers, Danco Laboratories and GenBioPro.[5][6]

The manufacturers argued that the 5th Circuit's ruling would cause immediate chaos for patients, healthcare providers, and pharmacies, while fundamentally destabilizing the pharmaceutical industry. They warned that allowing federal judges to second-guess the FDA's scientific expertise could set a dangerous precedent, threatening the approval status of countless other medications.[2][4]

The Supreme Court's handling of the case highlights its increasing reliance on the "shadow docket"—a term used to describe emergency orders and summary decisions issued outside the Court's regular merits docket. Justice Samuel Alito, who oversees emergency appeals from the 5th Circuit, initially granted a brief administrative stay to give the full Court time to consider the matter.

When the full Court issued its 7-2 decision to extend the stay, Justices Clarence Thomas and Samuel Alito were the lone dissenters. In his dissent, Justice Thomas characterized the mailing of mifepristone as a "criminal enterprise" and explicitly invoked the Comstock Act, an obscure 1873 anti-obscenity law that prohibits the mailing of items intended for producing an abortion.[1][3]

The invocation of the Comstock Act signals a potential future battleground in reproductive rights litigation. While the Biden administration and reproductive health advocates argue the law has been obsolete for nearly a century and does not apply to lawful medical care, anti-abortion groups and conservative legal scholars are increasingly citing it as a mechanism to enact a de facto national ban on abortion medications.[1][5]

For now, the Supreme Court's order preserves the status quo, but it does not resolve the underlying legal questions. The case now returns to the 5th Circuit for full briefing and oral arguments on the merits of Louisiana's claims. Legal experts widely expect that regardless of how the appellate court rules, Louisiana v. FDA will eventually make its way back to the Supreme Court for a final, definitive ruling on the FDA's authority and the future of medication abortion in the United States.[6]